Leerink Partners analyst Richard Newitter maintained a Buy rating on Organogenesis Holdings (NASDAQ:ORGO) Inc on Wednesday, setting a price target of $13, which is approximately 36.99% above the present share price of $9.49.
Newitter expects Organogenesis Holdings Inc to post earnings per share (EPS) of $0.20 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Organogenesis Holdings, with an average price target of $12.25.
The analysts price targets range from a high of $14 to a low of $9.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $100.8 million and a net profit of $22.98 million. The company's market cap is $1.21 billion.
According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 27.1% and a 71.22% success rate.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.